arrow
S

Scott Kopetz

The University of Texas MD Anderson Cancer Center
H指数:109
被引数:5.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

作者更正:一类选择性抑制EGFR和PI3K的先导抑制剂提供了一种靶向适应性耐药的单分子方法

2026-10-120
OAAI
ASO Visual Abstract: Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial

ASO 可视化摘要:对于可切除肝脏和不可切除肺部转移的结直肠腺癌(LUNA):肝切除术联合化疗或单独化疗的随机II期试验

2026-07-250
PRE
Patterns of progression and survival in patients with mismatch repair deficient/ microsatellite instability- high metastatic colorectal cancer treated with immunotherapy

错配修复缺陷/微卫星高度不稳定转移性结直肠癌患者接受免疫治疗后的进展模式和生存情况

2026-07-200
OAAI
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3

随机对照研究:比较恩考拉非尼、西妥昔单抗和FOLFIRI方案与FOLFIRI联合或不联合贝伐珠单抗治疗BRAF V600E突变型结直肠癌——BREAKWATER队列研究3组

2026-05-310
OAAI
Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures

T细胞受体基因组分析揭示了林奇综合征特有的免疫特征

2026-04-030
OAAI
Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial

结直肠癌腺癌可切除肝脏与不可切除肺部转移灶的肝切除术联合化疗或单纯化疗治疗(LUNA):一项随机Ⅱ期临床试验

2025-12-100
PRE
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer

RASH3D19通过正反馈回路介导KRAS突变癌症中的RAS激活

2025-12-010
PRE
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest

肿瘤浸润细菌破坏癌症上皮细胞相互作用并诱导细胞周期停滞

2025-10-160
OAAI
Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis

脱细胞细胞外基质支架用于构建微小结直肠癌肝转移的休眠景观

2025-10-130
OAAI
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer

炎症和突变负担与nivolumab或ipilimumab联合疗法的疗效在结直肠癌中存在差异关联。

2025-10-060
OAAI
Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers

针对syndecan-1轴的治疗性靶向克服了胃肠道癌症中针对KRAS疗法的获得性耐药。

2025-07-250
OAAI
Tumoral and circulating genomic landscape inform survival differences in colorectal carcinomatosis

肿瘤性和循环基因组景观揭示结直肠癌癌转移生存差异

2025-05-010
PRE
Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy
2025-01-080
OA